```html

Kernicteric Sclera

Kernicteric sclera (also called “jaundiced white of the eye”) is a striking yellow discoloration of the sclera—the white part of the eye. While the term is most often used in newborns, it can appear in older children and adults when bilirubin levels become abnormally high. Understanding why the sclera turns yellow, what other signs accompany it, and when urgent medical attention is required can help parents, caregivers, and patients act quickly.

What is Kernicteric sclera?

Kernicteric sclera refers to the yellow staining of the sclera caused by the deposition of the pigment bilirubin in the connective tissue of the eye. Bilirubin is a breakdown product of hemoglobin; when its concentration in the bloodstream rises (hyperbilirubinemia), it can infiltrate lipid‑rich tissues such as the sclera, skin, and mucous membranes, giving them a yellow hue.

In newborns, the timing of the yellowing is an important clue:

• Physiologic jaundice usually appears 2–4 days after birth, peaks around day 5, and resolves within 1–2 weeks.
• Pathologic jaundice may develop earlier, be more intense, or persist longer, indicating an underlying problem that requires evaluation.

In older patients, kernicteric sclera is less common but signals significant liver or hematologic disease. The presence of yellow sclera alone does not diagnose a specific condition, but it is an important visual marker that prompts further work‑up.

Common Causes

The following conditions are among the most frequent reasons for a yellow sclera:

• Physiologic newborn jaundice – immaturity of the newborn liver’s ability to conjugate bilirubin.
• Breast‑milk jaundice – elevated bilirubin due to substances in breast milk that interfere with bilirubin metabolism (usually after the first week).
• Hemolytic disease of the newborn (ABO or Rh incompatibility) – rapid destruction of fetal red cells leads to high unconjugated bilirubin.
• Crigler‑Najjar syndrome (type I & II) – genetic deficiency of UDP‑glucuronosyltransferase, causing severe unconjugated hyperbilirubinemia.
• Gilbert’s syndrome – mild, inherited reduction in bilirubin‑conjugating enzyme activity, often unmasked by fasting, illness, or medication.
• Maternal drugs that displace bilirubin – e.g., certain sulfonamides, ceftriaxone, or protease inhibitors.
• Sepsis or severe infection in newborns – can impair liver function and increase bilirubin production.
• Liver diseases in older children/adults – hepatitis, biliary obstruction, cirrhosis, or cholestasis.
• Hemolytic anemias – sickle cell disease, G6PD deficiency, hereditary spherocytosis.
• Medication‑induced cholestasis – certain antibiotics, anabolic steroids, or antiretrovirals.

Associated Symptoms

Because kernicteric sclera is a sign of systemic bilirubin excess, patients often experience other visible or systemic clues:

• Yellow skin (jaundice) – usually starts on the face and progresses downward.
• Dark urine – bilirubin excreted in urine gives a tea‑colored appearance.
• Pale, clay‑colored stools – indicates lack of bilirubin reaching the intestines.
• Feeding difficulties or poor weight gain in infants.
• Lethargy, irritability, or poor alertness – especially worrisome in newborns.
• Enlarged liver or spleen (hepatosplenomegaly) – common in hemolytic disorders.
• Fever or signs of infection – suggests sepsis or cholangitis.
• Neurological signs – high levels of unconjugated bilirubin can cross the blood‑brain barrier causing kernicterus (absorptive brain injury) presenting as hypotonia, seizures, or poor reflexes.

When to See a Doctor

Any yellow discoloration of the white of the eye should prompt an evaluation, but urgent care is needed if any of the following are present:

• Infants < 2 weeks old with scleral yellowing that appears < 24 hours after birth.
• Rapidly intensifying yellow color (e.g., the sclera turns noticeably more yellow within hours).
• Baby is difficult to wake, excessively sleepy, or has poor feeding.
• Fever, lethargy, or signs of infection accompany the jaundice.
• Dark urine or pale stools develop.
• Parents notice swelling of the abdomen, liver, or spleen.
• In older children or adults, new yellow sclera together with abdominal pain, itching, weight loss, or a history of liver disease.

Because high bilirubin can cause irreversible brain injury (kernicterus) in newborns, early medical assessment is critical.

Diagnosis

Doctors combine a focused history, physical examination, and targeted laboratory testing.

History & Physical Exam

• Onset, duration, and progression of yellowing.
• Feeding patterns, weight change, and urine/stool color.
• Maternal blood type, prenatal care, and any known incompatibilities.
• Family history of liver or hemolytic disorders.
• Examination of the skin, sclera, abdomen (for hepatomegaly), and neurologic status.

Laboratory Tests

• Serum total bilirubin with fractionation (unconjugated vs. conjugated). Levels > 12 mg/dL in term infants or > 15 mg/dL in pre‑terms often warrant treatment.
• Complete blood count (CBC) & reticulocyte count – assesses hemolysis.
• Blood type and Coombs test – detects immune hemolysis (ABO/Rh incompatibility).
• Liver function panel (ALT, AST, ALP, GGT, albumin) – evaluates hepatic injury.
• Serum haptoglobin, lactate dehydrogenase (LDH) – supportive for hemolysis.
• Urine bilirubin and urobilinogen – helps differentiate conjugated vs. unconjugated jaundice.
• Genetic testing – when Crigler‑Najjar or Gilbert’s syndrome is suspected.

Imaging (if indicated)

• Abdominal ultrasound – assesses biliary tree for obstruction or gallstones.
• Head ultrasound (in newborns) – screens for kernicterus‑related basal ganglia changes if bilirubin is extremely high.

Treatment Options

Treatment targets the underlying cause and, most importantly, reduces serum bilirubin to safe levels.

Newborns

• Phototherapy – blue‑light exposure converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation. Most cases improve within 24–48 hours.
• Exchange transfusion – reserved for bilirubin levels that threaten the brain (e.g., > 20 mg/dL in term infants) or when phototherapy fails.
• Intravenous immunoglobulin (IVIG) – used in hemolytic disease of the newborn to reduce antibody‑mediated hemolysis.
• Optimized feeding – frequent breast‑ or formula‑feeds increase stool output and bilirubin elimination.

Older Children & Adults

• Treat underlying hemolysis – e.g., folic acid supplementation, avoidance of triggering drugs, or specific therapy for sickle cell disease.
• Manage liver disease – antiviral therapy for hepatitis, biliary drainage for obstruction, or steroids for autoimmune hepatitis.
• Ursodeoxycholic acid – improves bile flow in cholestatic conditions.
• Phenobarbital – can induce bilirubin‑conjugating enzymes in Crigler‑Najjar type II.
• Liver transplant – considered for end‑stage liver disease or severe Crigler‑Najjar type I.

Home & Supportive Care

• Maintain adequate hydration (breast milk, formula, or clear fluids).
• Track stool color; aim for yellow, seedy stools indicating bilirubin excretion.
• Avoid drugs known to displace bilirubin (e.g., certain sulfonamides, high‑dose vitamin A).
• Keep regular follow‑up appointments for repeat bilirubin measurements.

Prevention Tips

• Prenatal care – early testing of maternal blood type and antibody screen reduces risk of hemolytic disease.
• Prompt newborn screening – bilirubin checks before discharge and at 24–48 hours for at‑risk infants.
• Early and frequent feeding – helps move bilirubin through the gut.
• Avoid unnecessary medications – discuss all drugs with a pediatrician before giving them to an infant.
• Vaccinate against hepatitis A & B – protects liver health later in life.
• Screen for hereditary conditions – family history of Gilbert’s, Crigler‑Najjar, or hemolytic anemias should prompt genetic counseling.
• Maintain a healthy weight and limit alcohol consumption in adults to reduce the risk of liver dysfunction.

Emergency Warning Signs

Key Take‑aways

Kernicteric sclera is an eye‑visible marker of elevated bilirubin. While it is often benign and self‑limited in healthy newborns, it can herald serious conditions such as hemolytic disease, liver failure, or, in extreme cases, kernicterus. Early recognition, appropriate laboratory testing, and timely treatment—especially phototherapy in infants—prevent complications. When in doubt, seek medical advice promptly; the eyes can tell you when your body needs help.

---

References:

1. Mayo Clinic. “Jaundice in newborns.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/newborn-jaundice
2. American Academy of Pediatrics. “Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.” 2022. https://pediatrics.aappublications.org/content/149/2/e2021054560
3. Cleveland Clinic. “Kernicterus.” 2024. https://my.clevelandclinic.org/health/diseases/21295-kernicterus
4. National Institutes of Health. “Crigler‑Najjar syndrome.” GeneReviews, 2023. https://www.ncbi.nlm.nih.gov/books/NBK1225/
5. World Health Organization. “Maternal and child health: jaundice.” 2022. https://www.who.int/health-topics/jaundice

```